GSK Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

54.290

Open

54.150

VWAP

53.58

Vol

3.67M

Mkt Cap

106.79B

Low

53.135

Amount

196.82M

EV/EBITDA(TTM)

7.66

Total Shares

2.00B

EV

95.40B

EV/OCF(TTM)

13.24

P/S(TTM)

2.51

GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).

Show More

Events Timeline

(ET)

2026-06-30

14:00:00

AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization

2026-06-30

13:30:00

Anthropic Launches Claude Science for Scientific Research

2026-06-24 (ET)

2026-06-24

10:01:00

GSK Launches Tender Offer for Nuvalent at $124 per Share

2026-06-17 (ET)

2026-06-17

11:30:00

GSK and Spero Therapeutics Get FDA Approval for Utebzi Antibiotic

2026-06-15 (ET)

2026-06-15

13:00:00

CMS Proposes Permanent Drug Price Negotiation Framework

2026-06-12 (ET)

2026-06-12

07:31:00

GSK's Momelotinib Receives Orphan Drug Designation

2026-06-09 (ET)

2026-06-09

16:20:00

Major Averages Dip as Market Awaits CPI Report

2026-06-09

12:00:00

Major Averages Broadly Lower as Market Awaits CPI Report

News

Globenewswire

06-24Globenewswire

Oncology Research Sees New Opportunities with DDR Inhibitors

Newsfilter

06-24Newsfilter

Oncology Research Sees New Opportunities with DDR Inhibitors

Globenewswire

06-22Globenewswire

Investigation Alerts for Multiple Company Acquisitions

Newsfilter

06-17Newsfilter

First Oral Carbapenem Antibiotic Approved in the US

Globenewswire

06-17Globenewswire

First Oral Carbapenem Antibiotic Approved in the US

Newsfilter

06-17Newsfilter

First Oral Carbapenem Antibiotic Approved in the US

6 Analyst Rating

Wall Street analysts forecast GSK stock price to rise

1 Buy

2 Hold

3 Sell

Moderate Sell

Current: 0.000

Low

20.15

Averages

38.72

High

55.60

Current: 0.000

Low

20.15

Averages

38.72

High

55.60

HSBC

Reduce

to

Hold

upgrade

AI Analysis

2026-07-06

New

Reason

HSBC

Price Target

AI Analysis

2026-07-06

New

upgrade

Reduce

to

Hold

Reason

HSBC upgraded GSK to Hold from Reduce with a price target of 1,860 GBp, up from 1,500 GBp. The key risk for the stock was a large patent cliff and lack of pipeline strength to replace the earnings power, but the change in management and recent willingness to reinvest in the pipeline to drive future growth suggests that the company \"might be turning a corner,\" the analyst tells investors.

Citi

Neutral

to

Hold

downgrade

2026-05-06

Reason

Citi

Price Target

2026-05-06

downgrade

Neutral

to

Hold

Reason

Citi lowered the firm's price target on GSK to 2,100 GBp from 2,250 GBp and keeps a Neutral rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GSK

Unlock Now

Valuation Metrics

The current forward P/E ratio for GSK plc (GSK.N) is 22.47, compared to its 5-year average forward P/E of 9.94. For a more detailed relative valuation and DCF analysis to assess GSK plc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

9.94

Current PE

22.47

Overvalued PE

14.22

Undervalued PE

5.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

8.10

Current EV/EBITDA

7.86

Overvalued EV/EBITDA

10.00

Undervalued EV/EBITDA

6.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

2.18

Current PS

3.02

Overvalued PS

2.63

Undervalued PS

1.72

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what should i buy for long term on 60€

Intellectia · 146 candidates

Dividend Yield Ttm: >= 0Price: <= $60.00Quarter Revenue Yoy Growth: >= 0.0%Market Cap Category: large, midEps Ttm: >= 0Net Margin: >= 0.00Beta: LowRisk, ModerateRiskPe Ttm: <= 35Moving Average Relationship: PriceAboveMA200Annual Revenue Yoy Growth: >= 0.0%

Ticker

Name

Market Cap$

Sumitomo Mitsui Financial Group, Inc

155.85B

Banco Bilbao Vizcaya Argentaria SA

144.23B

Enbridge Inc

118.09B

GSK plc

107.50B

Itau Unibanco Holding SA

89.50B

Mondelez International Inc

78.19B

Intellectia · 1 candidates

Volume: >= -100Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Option Unusual Activity: TrueWeekly Average Dollar Volume: >= -100Macd: bullish

Ticker

Name

Market Cap$

GSK plc

105.95B

what stocks should I day trade today

Intellectia · 1 candidates

Region: USVolume: >= 1Rsi Category: moderateRelative Vol: >= 1.20Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA5, PriceCrossAboveMA20Is Optionable: TrueOption Unusual Activity: TrueWeekly Average Dollar Volume: >= 1Monthly Average Dollar Volume: >= 1

Ticker

Name

Market Cap$

GSK plc

102.61B

What other stocks would be good

Intellectia · 6 candidates

Region: USVolume: >= 1,000,000List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceBelowMA20Is Optionable: TrueOption Unusual Activity: TrueMonthly Average Dollar Volume: >= 50,000,000News Driver: Positive, Negative

Ticker

Name

Market Cap$

NVIDIA Corp

5.38T

Broadcom Inc

1.99T

Oracle Corp

536.70B

Exxon Mobil Corp

665.22B

PayPal Holdings Inc

39.15B

GSK plc

100.90B

which stick good for option today

Intellectia · 8 candidates

Price: $10.00 - $150.00Is Optionable: TrueOption Iv Rank: 30 - 90Option Unusual Activity: True

Ticker

Name

Market Cap$

Exxon Mobil Corp

616.67B

BILL Holdings Inc

3.94B

Figma Inc

9.77B

PayPal Holdings Inc

45.78B

Unity Software Inc

11.09B

GSK plc

112.05B

best stocks for options trading

Intellectia · 4 candidates

Market Cap: >= 10.00BIs Optionable: TrueOption Iv Rank: >= 50Option Unusual Activity: TrueMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Exxon Mobil Corp

714.47B

Oracle Corp

399.20B

Delta Air Lines Inc

41.27B

GSK plc

108.43B

ok the us stocks instead

Intellectia · 197 candidates

Price: >= $5.00Market Cap Category: large, mid, smallGross Margin: >= 20.00Net Margin: >= 5.00Debt Equity: <= 150List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Annual Eps Yoy Growth: >= 5.0%Annual Revenue Yoy Growth: >= 5.0%

Ticker

Name

Market Cap$

KLA Corp

199.83B

Salesforce Inc

182.52B

Amphenol Corp

179.54B

Southern Copper Corp

178.81B

Charles Schwab Corp

166.81B

Stryker Corp

148.28B

find me a great swing option play

Intellectia · 6 candidates

Price: $10.00 - $200.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Is Optionable: TrueOption Unusual Activity: TrueOne Week Rise Prob: 0 - 100One Week Predict Return: 0.0% - 100.0%

Ticker

Name

Market Cap$

PayPal Holdings Inc

41.92B

SentinelOne Inc

4.58B

Delta Air Lines Inc

46.05B

Kennametal Inc

3.06B

Pegasystems Inc

7.66B

GSK plc

116.53B

Intellectia · 107 candidates

Market Cap: >= 10.00BRelative Vol: >= 3New High Low: 52w_HighMoving Average Relationship: PriceAboveMA200Support Resistance Relationship: PriceBreakResistance

Ticker

Name

Market Cap$

Walmart Inc

1.04T

Exxon Mobil Corp

622.98B

Johnson & Johnson

577.58B

Coca-Cola Co

338.69B

Caterpillar Inc

336.58B

Cisco Systems Inc

332.13B

what stocks look ready for a breakout

Intellectia · 103 candidates

Market Cap: >= 2.00BRegion: USPrice: $10.00 - $120.00Relative Vol: >= 1.50New High Low: 52w_HighBeta: ModerateRisk, HighRisk, LowRisk, NegativeBetaList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Support Resistance Relationship: PriceBreakResistanceMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Cisco Systems Inc

326.12B

Coca-Cola Co

335.18B

Carnival Corp

45.23B

Regions Financial Corp

26.27B

KeyCorp

24.94B

CSX Corp

74.09B

Whales Holding GSK

PRIMECAP Management Company

Armistice Capital LLC

Epoch Investment Partners, Inc.

Letko, Brosseau & Associates Inc.

Barclays Bank PLC

Tower Research Capital Europe Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is GSK plc (GSK) stock price today?

The current price of GSK is 53.32 USD — it has increased 0.43

What is GSK plc (GSK)'s business?

GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).

What is the price predicton of GSK Stock?

Wall Street analysts forecast GSK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is GSK plc (GSK)'s revenue for the last quarter?

GSK plc revenue for the last quarter amounts to 10.28B USD, increased 8.64

What is GSK plc (GSK)'s earnings per share (EPS) for the last quarter?

GSK plc. EPS for the last quarter amounts to 0.57 USD, increased 16.33

How many employees does GSK plc (GSK). have?

GSK plc (GSK) has 66841 emplpoyees as of July 08 2026.

What is GSK plc (GSK) market cap?

Today GSK has the market capitalization of 106.79B USD.